|
Zebrafish Models of Cancer
|
Z01 BC 010549
|
$773,747
|
$232,124
|
Hickstein, Dennis
|
CCR (NCI)
|
|
YALE COMPREHENSIVE CANCER CENTER
|
5P30CA016359-30
|
$1,889,710
|
$94,486
|
EDELSON, RICHARD
|
YALE UNIVERSITY
|
|
Women's Health Study: Continued Follow-up
|
5R01CA047988-18
|
$1,680,173
|
$336,035
|
BURING, JULIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Wnt Antagonist Gene Hypermethylation in Circulating DNA: Cancer Biomarker
|
Z01 BC 011050
|
$32,786
|
$3,279
|
Rubin, Jeffrey
|
CCR (NCI)
|
|
Web-based Family History Screening for Hereditary Breast Cancer Risk
|
5R21CA127837-02
|
$154,500
|
$154,500
|
ACHESON, LOUISE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Vitamin D and Ovarian Cancer Prevention and Treatment
|
5R01CA111334-04
|
$244,382
|
$244,382
|
BAI, WENLONG
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Vascular Leukocytes influence the tumor microenvironment
|
5R01CA124515-02
|
$303,810
|
$303,810
|
Conejo-Garcia, Jose
|
DARTMOUTH COLLEGE
|
|
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors
|
5R01CA116779-03
|
$271,456
|
$135,728
|
COUKOS, GEORGE
|
UNIVERSITY OF PENNSYLVANIA
|
|
Vaccine and radiation for the therapy of human cancers
|
Z01 BC 010975
|
$308,694
|
$61,739
|
Hodge, James
|
CCR (NCI)
|
|
Vaccine and Drug Combination Therapy for Human Cancers
|
Z01 BC 010661
|
$360,144
|
$72,029
|
Hodge, James
|
CCR (NCI)
|
|
UT M.D. Anderson Cancer Center
|
5U10CA045809-20
|
$1,758,769
|
$70,351
|
FISCH, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Using Diazeniumdiolate Chemistry to Design Nitric Oxide-Based Therapies
|
Z01 BC 005673
|
$1,225,024
|
$245,005
|
Keefer, Larry
|
CCR (NCI)
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-33S1
|
$74,165
|
$2,967
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
5P30CA014089-33
|
$6,658,653
|
$266,346
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research
|
2U54CA096297-06A1
|
$1,584,860
|
$126,789
|
FRONTERA-ROURA, WALTER
|
UNIVERSITY OF PUERTO RICO MED SCIENCES
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research
|
2U54CA096300-06A1
|
$1,216,467
|
$182,470
|
DUBOIS, RAYMOND
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UNRESOLVED PUBLIC HEALTH ISSUES RELATED TO HT AND CANCER
|
5P01CA017054-30
|
$2,034,926
|
$671,526
|
HENDERSON, BRIAN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-24S1
|
$80,987
|
$2,430
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
5P30CA036727-24
|
$1,553,887
|
$46,617
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-09
|
$2,180,816
|
$2,180,816
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-04S1
|
$60,563
|
$3,028
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO
|
|
University of New Mexico Cancer Center Support
|
5P30CA118100-04
|
$1,332,378
|
$66,619
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-21S1
|
$61,058
|
$1,221
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
5P30CA046592-21
|
$5,994,681
|
$119,894
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Univ.of Calif., Irvine Cancer Center Support Grant
|
3P30CA062203-13S4
|
$2,630,152
|
$52,603
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Univ.of Calif., Irvine Cancer Center Support Grant
|
3P30CA062203-13S5
|
$61,584
|
$1,232
|
MEYSKENS, FRANK
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
Tumor-Associated Antigens in Early Stage Serous Carcinoma
|
5R01CA122581-03
|
$304,849
|
$304,849
|
Roden, Richard
|
JOHNS HOPKINS UNIVERSITY
|
|
Tumor Suppressor Protein, p53
|
Z01 BC 005599
|
$589,066
|
$147,267
|
Appella, Ettore
|
CCR (NCI)
|
|
Tumor metastasis: Biobehavioral mechanisms
|
5R01CA110793-05
|
$329,472
|
$329,472
|
SOOD, ANIL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor maintenance and development in mouse models
|
5U01CA105492-05
|
$464,773
|
$153,375
|
VARMUS, HAROLD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Tumor Host Range Mutants of Polyoma and Their Targets
|
5R01CA092520-08
|
$617,981
|
$617,981
|
BENJAMIN, THOMAS
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
|
Treatment of Chemotherapy-Resistant Human Ovarian Cancer by Administration of CPE
|
1R01CA122728-01A2
|
$346,272
|
$346,272
|
SANTIN, ALESSANDRO
|
YALE UNIVERSITY
|
|
Translational Research in Cancer
|
2P30CA056036-09
|
$3,116,058
|
$31,161
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-09S1
|
$63,390
|
$634
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Applications of mda-7/IL-24 in Cancer
|
7P01CA104177-04
|
$1,329,682
|
$452,092
|
FISHER, PAUL
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Transforming growth factor beta signaling pathways
|
5R01CA055536-17
|
$308,158
|
$77,040
|
HOWE, PHILIP
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Training of Academic Gynecologic Oncologists
|
5T32CA101642-04
|
$376,736
|
$124,323
|
GERSHENSON, DAVID
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
TRAIL-induced Cell Death in Breast Cancer Cells
|
Z01 SC 007263
|
$324,990
|
$32,499
|
Lipkowitz, Stanley
|
CCR (NCI)
|
|
TRAIL Receptor Signaling in Human Tumors
|
1R01CA124545-01A1
|
$413,398
|
$206,699
|
THORBURN, ANDREW
|
UNIVERSITY OF COLORADO DENVER
|
|
Total Synthesis of Anticancer Agents Superstolides A & B
|
5R01CA109208-02
|
$270,014
|
$67,504
|
JIN, ZHENDONG
|
UNIVERSITY OF IOWA
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-12
|
$203,525
|
$81,410
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
Topoisomerase I Inhibitors in Leukemia and Solid Tumors
|
5R01CA073709-10
|
$221,813
|
$55,453
|
KAUFMANN, SCOTT
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Tools for Large-Scale Analysis of Driver Pathways
|
1R21CA135877-01
|
$221,400
|
$73,062
|
KARCHIN, RACHEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Tissue Array Research Program
|
Z01 BC 010923
|
$561,297
|
$28,065
|
Hewitt, Stephen
|
CCR (NCI)
|
|
Therapeutic targeting of HSP90-dependent signaling
|
5R01CA104378-05
|
$258,036
|
$258,036
|
KARNITZ, LARRY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
3R01CA115483-04S1
|
$59,963
|
$59,963
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-04
|
$301,109
|
$301,109
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis
|
Z01 SC 000165
|
$288,382
|
$72,096
|
Birrer, Michael
|
CCR (NCI)
|
|
The use of chitosan for cancer vaccine delivery
|
Z01 BC 010969
|
$369,762
|
$73,953
|
Greiner, Jack
|
CCR (NCI)
|
|
The Self Regulation Model in BRCA 1/2 Genetic Counseling
|
1R03CA128459-01A2
|
$75,000
|
$37,500
|
Kelly, Kimberly
|
OHIO STATE UNIVERSITY
|
Total relevant funding to Ovarian Cancer for this search: $100,038,119
|